Elevated CD14 levels in CSF from patients with Alzheimer’s disease and elevated osteopontin levels in CSF from patients with Parkinson’s disease were detected using both the screening and confirmatory assays, rendering them promising biomarker candidates. This evidence concerns the gene SPP1 and early-onset autosomal dominant Alzheimer disease.